Support for youth at clinical high risk for psychosis in Tunisia
Part of Mental health clinical trials.
This study tests a support program for young people in Tunisia who show early signs of possible psychosis. It aims to help them before more serious symptoms develop.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have early warning signs of psychosis, called clinical high risk
- If you are under 18, a parent or guardian must agree to the study
- You must have an IQ of 70 or higher
- You must speak Arabic, French, or English well enough to answer questions
- You must live near Razi University Hospital in Tunisia
- You must not have a brain problem like epilepsy or a serious head injury
- You must not have a history of heavy alcohol or drug use in the last 6 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a telehealth (video/phone) version of cognitive behavioral therapy to help young people who are at risk for developing psychosis. It may help by teaching skills to reduce symptoms and improve coping, with support from a key family or close person.
This study explores how young people who are at high risk for psychosis or have had a first episode experience mindfulness. It uses interviews to understand their personal experience, which could help improve future treatments.
This trial tests whether mindfulness training can help young people at high risk for psychosis avoid developing a full psychotic disorder. If you are between 18 and 30 and have early signs of psychosis, this program might be a way to get support and learn skills to stay well.
This study is testing a new French version of a questionnaire (SPI-CY) that helps doctors better understand early signs of psychosis in teenagers. If you are 12 to 17 and already being checked for these signs, you may be able to help improve the tool.
This study tests a program to help young people who are at risk for psychosis and have had suicidal thoughts or behaviors. The program also involves a caregiver, like a family member, to provide support.
This trial tests a new drug called MT1988 in people who show early warning signs of psychosis. Researchers want to see if it changes certain markers in the body related to mental health.
Hear when a new Clinical High Risk for Psychosis (CHR) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.